AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 JAN 17 - (NewsRx.com & NewsRx.net) -- by Sonia Nichols, senior medical writer - Hormone replacement therapy can elevate the risk for insulin resistance in postmenopausal females.
The finding holds true regardless of whether or not a woman carries excess fat in her abdominal area, according to Alice S. Ryan and colleagues at the University of Maryland School of Medicine in Baltimore.
Ryan's group evaluated 28 obese, postmenopausal Caucasian women with sedentary lifestyles for differences in insulin sensitivity based on whether or not they were taking hormones, i.e., estradiol alone or estrogen plus progesterone. The researchers matched each women taking hormones with women of similar age, weight, and body mass index (BMI) who were not receiving hormone therapy.
Values for several measures of overall fat, abdominal fat, and other determinants of adiposity were similar in both groups and did not diverge with hormonal status, Ryan and coworkers said.
However, investigators did see differences between the hormonal and nonhormonal groups with respect to glucose utilization. Glucose utilization was 30% and 26% lower, respectively, in women taking estrogen alone and estrogen plus progesterone than in women not taking hormones at all (Hormone replacement therapy, ...